Ashland Inc. Reports $877 Million Net Loss and 16% Revenue Decline in Latest 10-Q

Ashland Inc. reported a significant financial downturn in its latest 10-Q filing for the nine months ending June 30, 2025, with a net loss of $877 million, compared to a profit of $153 million in the same period last year. The company's diluted earnings per share from continuing operations fell to $(18.39), down from $3.57 a year earlier. The decline was primarily attributed to a non-cash goodwill impairment charge of $706 million, which impacted both the Life Sciences and Specialty Additives segments. Revenue for the nine-month period also decreased by 16% to $1.35 billion, down from $1.61 billion in the previous year, driven by divestitures and lower sales volumes.

In terms of operational changes, Ashland completed the sale of its Avoca business for approximately $16 million in March 2025, which did not qualify for discontinued operations treatment. The company also recorded an impairment charge of $183 million related to this divestiture. Additionally, Ashland's restructuring efforts included a $30 million plan aimed at offsetting the impact of the Nutraceuticals business sale, which was completed in fiscal 2024. The restructuring is expected to yield savings of approximately $20 million, with more than half anticipated to be realized in fiscal 2025.

The company’s operational metrics reflected a challenging environment, with total sales across its reportable segments declining. Life Sciences sales fell to $468 million from $617 million, Personal Care dropped to $426 million from $473 million, and Specialty Additives decreased to $380 million from $429 million. The decline in sales was attributed to lower volumes, unfavorable pricing, and the impact of divestitures. The company’s total employee headcount was approximately 2,960, with ongoing efforts to streamline operations and reduce costs.

Looking ahead, Ashland has updated its fiscal 2025 outlook, projecting sales between $1.825 billion and $1.850 billion, with Adjusted EBITDA expected in the range of $400 million to $410 million. The company anticipates a stable but subdued macroeconomic environment, with mixed demand trends across its segments. Ashland is focusing on innovation and operational efficiencies to mitigate near-term pressures and position itself for improved performance in the future. The company continues to monitor external factors such as tariffs and geopolitical tensions that may impact its operations.